1. | hockeynutz4 | |
2. | er09 | |
3. | bkmetzfrontierco | |
4. | Fibonacci | |
5. | adelaydpec9 |
1. | hockeynutz4 | |
2. | er09 | |
3. | bkmetzfrontierco | |
4. | Fibonacci | |
5. | adelaydpec9 |
1. | johnknickerb 02/07/2018 FDA approves Biktarvy for treatment of HIV-1 |
2. | er09 02/22/2018 Long news? - J.P. Morgan Weighs in on Sangamo Therapeutics Inc's (SGMO) Collaboration with Kite |
3. | bkmetzfrontierco 01/31/2018 Finbox.io points out that Gilead shares are ultra cheap compared to their peers right now. |
4. | adelaydpec9 03/07/2018 Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elv |
5. | ppfef80 03/05/2018 Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed |
6. | blackclouds 10/19/2017 $GILD......... 51% of patients that recieved Yescarta are in complete remission |
7. | adelaydpec9 02/22/2018 Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer |
8. | Fibonacci 10/18/2017 price set at $373,000 |
9. | TheGriper 02/18/2018 A federal judge in Delaware has overturned a jury's verdict |
10. | hockeynutz4 02/07/2018 Nice to see them taking action |